35244188|t|DYRK1A suppression attenuates HIF-1alpha accumulation and enhances the anti-liver cancer effects of regorafenib and sorafenib under hypoxic conditions.
35244188|a|Hypoxia promotes drug resistance and induces the expression of hypoxia inducible factor (HIF)-1alpha in liver cancer cells. However, to date, no selective HIF-1alpha inhibitor has been clinically approved. The aim of this study is to investigate a drug-targetable molecule that can regulate HIF-1alpha under hypoxia. The present study demonstrated that hyperactivation of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A)/HIF-1alpha signaling was associated with an increased risk of liver cancer. In addition, DYRK1A knockdown using small interfering RNA transfection or treatment with harmine, a natural alkaloid, significantly reduced the protein expression levels of HIF-1alpha in liver cancer cells under hypoxic conditions in vitro. Conversely, DYRK1A overexpression-vector transfection in liver cancer cell lines notably induced HIF-1alpha expression under the same conditions. Furthermore, DYRK1A was shown to interact and activate STAT3 under hypoxia to regulate HIF-1alpha expression. These findings indicated that DYRK1A may be a potential upstream activator of HIF-1alpha and positively regulate HIF-1alpha via the STAT3 signaling pathway in liver cancer cells. Additionally, treatment with harmine attenuated the proliferative ability of liver cancer cells under hypoxic conditions using sulforhodamine B and colony formation assay. Furthermore, DYRK1A knockdown could significantly enhance the anti-liver cancer effects of regorafenib and sorafenib under hypoxia. Co-treatment with harmine and either regorafenib or sorafenib also promoted cell death via the STAT3/HIF-1alpha/AKT signaling pathway under hypoxia using PI staining and western blotting. Overall, the results from the present study suggested that DYRK1A/HIF-1alpha signaling may be considered a novel pathway involved in chemoresistance, thus providing a potentially effective therapeutic regimen for treating liver cancer.
35244188	0	6	DYRK1A	Gene	1859
35244188	30	40	HIF-1alpha	Gene	3091
35244188	76	88	liver cancer	Disease	MESH:D006528
35244188	100	111	regorafenib	Chemical	MESH:C559147
35244188	116	125	sorafenib	Chemical	MESH:D000077157
35244188	132	139	hypoxic	Disease	MESH:D002534
35244188	152	159	Hypoxia	Disease	MESH:D000860
35244188	215	252	hypoxia inducible factor (HIF)-1alpha	Gene	3091
35244188	256	268	liver cancer	Disease	MESH:D006528
35244188	307	317	HIF-1alpha	Gene	3091
35244188	443	453	HIF-1alpha	Gene	3091
35244188	460	467	hypoxia	Disease	MESH:D000860
35244188	524	585	dual-specificity tyrosine-phosphorylation-regulated kinase 1A	Gene	1859
35244188	587	593	DYRK1A	Gene	1859
35244188	595	605	HIF-1alpha	Gene	3091
35244188	657	669	liver cancer	Disease	MESH:D006528
35244188	684	690	DYRK1A	Gene	1859
35244188	760	767	harmine	Chemical	MESH:D006247
35244188	844	854	HIF-1alpha	Gene	3091
35244188	858	870	liver cancer	Disease	MESH:D006528
35244188	883	890	hypoxic	Disease	MESH:D002534
35244188	924	930	DYRK1A	Gene	1859
35244188	969	981	liver cancer	Disease	MESH:D006528
35244188	1009	1019	HIF-1alpha	Gene	3091
35244188	1071	1077	DYRK1A	Gene	1859
35244188	1113	1118	STAT3	Gene	6774
35244188	1125	1132	hypoxia	Disease	MESH:D000860
35244188	1145	1155	HIF-1alpha	Gene	3091
35244188	1198	1204	DYRK1A	Gene	1859
35244188	1246	1256	HIF-1alpha	Gene	3091
35244188	1281	1291	HIF-1alpha	Gene	3091
35244188	1300	1305	STAT3	Gene	6774
35244188	1327	1339	liver cancer	Disease	MESH:D006528
35244188	1376	1383	harmine	Chemical	MESH:D006247
35244188	1424	1436	liver cancer	Disease	MESH:D006528
35244188	1449	1456	hypoxic	Disease	MESH:D002534
35244188	1474	1490	sulforhodamine B	Chemical	MESH:C022027
35244188	1532	1538	DYRK1A	Gene	1859
35244188	1586	1598	liver cancer	Disease	MESH:D006528
35244188	1610	1621	regorafenib	Chemical	MESH:C559147
35244188	1626	1635	sorafenib	Chemical	MESH:D000077157
35244188	1642	1649	hypoxia	Disease	MESH:D000860
35244188	1669	1676	harmine	Chemical	MESH:D006247
35244188	1688	1699	regorafenib	Chemical	MESH:C559147
35244188	1703	1712	sorafenib	Chemical	MESH:D000077157
35244188	1746	1751	STAT3	Gene	6774
35244188	1752	1762	HIF-1alpha	Gene	3091
35244188	1763	1766	AKT	Gene	207
35244188	1791	1798	hypoxia	Disease	MESH:D000860
35244188	1898	1904	DYRK1A	Gene	1859
35244188	1905	1915	HIF-1alpha	Gene	3091
35244188	2061	2073	liver cancer	Disease	MESH:D006528
35244188	Association	MESH:C559147	MESH:D002534
35244188	Positive_Correlation	1859	3091
35244188	Association	MESH:D006528	6774
35244188	Association	3091	6774
35244188	Association	MESH:C559147	1859
35244188	Negative_Correlation	MESH:D006247	3091
35244188	Positive_Correlation	MESH:D000860	3091
35244188	Association	MESH:D006528	1859
35244188	Negative_Correlation	MESH:D006247	1859
35244188	Negative_Correlation	MESH:D006247	MESH:D002534
35244188	Comparison	MESH:C559147	MESH:D000077157
35244188	Association	MESH:D006247	207
35244188	Association	MESH:D006528	3091
35244188	Association	MESH:C559147	3091
35244188	Association	MESH:D002534	1859
35244188	Negative_Correlation	MESH:D000077157	MESH:D006528
35244188	Association	MESH:D000860	1859
35244188	Association	1859	6774
35244188	Negative_Correlation	MESH:C559147	MESH:D006528
35244188	Association	MESH:D000077157	MESH:D002534
35244188	Negative_Correlation	MESH:D006247	MESH:D000860
35244188	Cotreatment	MESH:D000077157	MESH:D006247
35244188	Negative_Correlation	MESH:C022027	MESH:D006247
35244188	Association	MESH:D000077157	1859
35244188	Negative_Correlation	MESH:D006247	MESH:D006528

